Carla Frederick, MD
Pulmonary Disease · Buffalo, NYNPI 1093913519
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $373 of the $458 with a category attached, or 81.6%. 4 manufacturers reported payments, led by Mylan Specialty L.p. at 50.0% of the total. 2025 is the largest year on record at $121, 3.5 times the $35 reported in 2020. That places this record below the midpoint for pulmonary disease clinicians in NY, where the typical reported total is $756.
Across 10 payments — averaging $45.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$229
- AstraZeneca$121
- Chiesi USA, Inc.$84
- Boston Scientific$23
Across 32 payments — averaging $30,360 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$965K
- AbbVie$6K
- Vivus LLC$464
What the payments were for
- Food & beverage$37382%
- Education$8418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 3 | $229 |
| AstraZeneca | 1 | $121 |
| Chiesi USA, Inc. | 5 | $84 |
| Boston Scientific | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$121
- TOBI Podhaler$106
How this compares
$458 in reported general payments places this provider in the 40th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 62 | $1,541,336 |
| ZenpepLipase/Protease/Amylase | 21 | $165,545 |
| Spiriva RespimatTiotropium Bromide | 43 | $24,674 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $9,744 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $9,185 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $9,102 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $8,597 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $8,500 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $8,408 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,776 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $6,481 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $6,317 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 140 | $5,674 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $1,548 |
| Ventolin HfaAlbuterol Sulfate | 18 | $1,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSymbicort, Breztri Aerosphere | $121 | $16,37345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Buffalo
- Nashat RabadiBuffalo$613K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.